EGFR and non-small cell lung carcinoma: Furthermore, downmodulation of CIP2A has been shown to be a prerequisite for sensitivity of EGFR wildtype NSCLC cell lines to EGFR tyrosine kinase inhibitors erlotinib [18,23] or afatinib [24] but also to natural compounds amentoflavone [25] and polyphyllins [26,27].